We advised the underwriters on the offering

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by AbbVie Inc. of $10 billion aggregate principal amount of senior notes in nine series, consisting of $500 million senior floating-rate notes due 2028, $1 billion of 4.500% senior notes due 2028, $1.25 billion of 4.650% senior notes due 2030, $1.5 billion of 4.875% senior notes due 2031, $1.25 billion of 5.050% senior notes due 2033, $1.5 billion of 5.300% senior notes due 2036, $1 billion of 5.450% senior notes due 2038, $1.5 billion of 6.000% senior notes due 2056 and $500 million of 6.100% senior notes due 2066. AbbVie expects to use the net proceeds from the offering to fund a portion of its cash payment obligations in connection with the acquisition of Apogee Therapeutics, Inc., and to pay fees, expenses and other amounts in connection therewith, and for other general corporate purposes, which may include the repayment or repurchase of outstanding debt.

AbbVie is a global, diversified research-based biopharmaceutical company positioned for success, with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics. AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

The Davis Polk capital markets team included partners Richard D. Truesdell Jr. and Roshni Banker Cariello, counsel Steven Glendon and associates Kerim K. Aksoy and Amanda Kim. The tax team included partner Patrick E. Sigmon and associates Omar Hersi and Peyton Williams. Partner David R. Bauer provided intellectual property advice. Counsel David A. Zilberberg provided environmental advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post